Condition: Severe Sepsis · Sponsor: Artcline GmbH
Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment. In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.
This description comes directly from the study's public registry record.
Erdmann J Zippel, RN · +4915772371146 · erdmann.zippel@artcline.de
Jens Altrichter, MD · +49 3814407030 · jens.altrichter@artcline.de
Always discuss trial participation with your own doctor first.
| Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin | Magdeburg, Germany | Recruiting |
| Universitätsmedizin Rostock, Abteilung KAI | Rostock, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06143137